Browsing Tag
ADA 2025
13 posts
MetaVia unveils synergistic liver disease data on DA-1241 and Efruxifermin at ADA 2025
MetaVia unveils ADA 2025 pre-clinical data showing DA-1241 and Efruxifermin combo improves MASH liver inflammation and fibrosis beyond monotherapies.
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.